Skip to content

Novavax NVAX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Moderna logo
ModernaMRNA
$1.5B+53.1%
Roivant Sciences logo
Roivant SciencesROIV
$5.02B+10.1%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$5.48B+15.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.95B+30.0%
ALN
Alnylam PharmaceuticalsALNY
$7.6B+1.3%
Gilead Sciences logo
Gilead SciencesGILD
$9.31B+14.3%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's additional paid-in capital?
Novavax (NVAX) reported additional paid-in capital of $4.55B in Q1 2026.
How has Novavax's additional paid-in capital changed year-over-year?
Novavax's additional paid-in capital increased by 0.8% year-over-year, from $4.51B to $4.55B.
What is the long-term trend for Novavax's additional paid-in capital?
Over 5 years (2020 to 2025), Novavax's additional paid-in capital has grown at a 12.4% compound annual growth rate (CAGR), from $2.54B to $4.54B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.